Search clinical trials for: Sintilimab Anlotinib Pemetrexed Cisplatin

Total 577 results

Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Mesothelioma, Malignant | Mesothelioma, Malignant Pleural | Mesothelioma Malignant Advanced

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Henan Provincial People's Hospital

Not yet recruiting

Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Ningbo No.2 Hospital

Not yet recruiting

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY)

Carcinoma, Non-Small-Cell Lung
Henan Cancer Hospital

Completed

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Extensive Disease Small Cell Lung Cancer

China
Sichuan Cancer Hospital and Research Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Lung Cancer Metastatic

China
Sun Yat-sen University

Not yet recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma

China
Changzhou Cancer Hospital of Soochow University

Unknown

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Shanghai Changzheng Hospital

Completed

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Colorectal Cancer | Immunotherapy | Sintilimab | First-line Treatment | Anlotinib | Chemo-free Therapy

China
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Sun Yat-sen University

Completed

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Radiotherapy | Sintilimab | Anlotinib | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Early Stage | Peg-aspargase | Phase Two | Open

China
Zhejiang Cancer Hospital

Completed

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Lung Cancer

China
Tang-Du Hospital

Completed

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Sintilimab and Anlotinib in Combination With Chemotherapy

China
Sichuan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Anlotinib

China
Zhejiang Cancer Hospital

Not yet recruiting

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

Small Cell Lung Cancer Extensive Stage
Guangzhou Medical University

Completed

Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Lung Adenocarcinoma | Brain Metastases

China
Lingyu Luo

Unknown

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Non-squamous Non-small Cell Lung Cancer
The First Affiliated Hospital with Nanjing Medical...

Unknown

Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

Non-squamous Non-small-cell Lung Cancer
The First Affiliated Hospital with Nanjing Medical...

Unknown

Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Swiss Group for Clinical Cancer Research

Completed

Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

Lung Cancer

Switzerland
Rong Tao

Recruiting

Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Yonsei University

Withdrawn

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

NSCLC
Shanghai Chest Hospital

Unknown

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Carcinoma | Non-small Cell Lung Cancer
Avistone Biotechnology Co., Ltd.

Not yet recruiting

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Non-Small-Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Grupo de Investigación Clínica en Oncología Radioterapia

Completed

Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Spain
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (ALTER-L043)

Resectable Locally Advanced Non-small Cell Lung Cancer

China
Xin-Hua Xu

Recruiting

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Oral Cavity Squamous Cell Carcinoma

China
Shanghai Chest Hospital

Recruiting

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Non-small Cell Lung Cancer | Minimal Residual Disease | Immunotherapy | Anti-angiogenesis

China
Masonic Cancer Center, University of Minnesota

Withdrawn

Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer

Cervical Cancer

United States
CanBas Co. Ltd.

Completed

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Solid Tumors | Malignant Pleural Mesothelioma

United States
Finnish Lung Cancer Group
Roche Pharma AG

Completed

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Non-small Cell Lung Cancer

Finland
CanBas Co. Ltd.

Completed

Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) (CBP08-02)

Metastatic Non-squamous Non Small Cell Lung Cancer

United States
Guangzhou Medical University

Unknown

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Non Small Cell Lung Cancer

China
Bayer

Terminated

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

Small Cell Lung Carcinoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

Lung Cancer | Non Small Cell Lung Cancer

United States
Eli Lilly and Company

Completed

Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Canada
BeiGene

Completed

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC

Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

A Prospective Multi-center Phase III Randomized Controlled Trial (NACA)

Carcinoma，Non-Small-Cell Lung

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer

Uterine Cervical Neoplasms | Sintilimab

China
Shanghai Chest Hospital

Unknown

First-line Combination Treatment Based on Anlotinib

Lung Cancer | Advanced Stage

China
Yonsei University

Active, not recruiting

A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma

Sarcoma

Korea, Republic of
Eli Lilly and Company

Completed

Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma

Gastrointestinal Neoplasms

Korea, Republic of
Pfizer

Completed

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

NSCLC (Non-small Cell Lung Cancer)

Hong Kong, China, Taiwan, Malaysia, Thailand
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

3

Subscribe